Ocular Therapeutix Currently Down Nine Consecutive Days, On Pace for Longest Losing Streak Since October 2019 -- Data Talk
Ocular Therapeutix Inc. (OCUL) is currently at $4.75, down $0.25 or 5% --Would be lowest close since Jan. 26, 2024, when it closed at $4.66 --Currently down 10 of the past 11 days --Currently down
Dow JonesApr 24 11:18 ET
Optimistic Buy Rating for Ocular Therapeutix Amid Early-Stage NPDR Study and Wet AMD Potential
TipRanksApr 22 01:46 ET
Baird Sees Weakness in Ocular Shares "Overdone" in Wake of Phase 1 Data
Seeking AlphaApr 19 18:07 ET
Why Super Micro Computer Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Super Micro Computer, Inc. (NASDAQ:SMCI) fell sharply during Friday's session.The company announced its third-quarter earnings date and did not provide preliminary estimates as it did with t
BenzingaApr 19 13:25 ET
Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Ocular Therapeutix (OCUL)
TipRanksApr 19 06:30 ET
Express News | HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Maintains $16 Price Target
Moomoo 24/7Apr 19 06:28 ET
Ocular Therapeutix Announces New Leadership and Incentive Plan Expansion
TipRanksApr 18 16:22 ET
Ocular Therapeutix Reports Positive Topline Data in Diabetic Retinopathy Trial; Shares Fall
Ocular Therapeutix (OCUL) said Thursday data from the phase 1 Helios study of Axpaxli showed that 46% of the patients had a 1- or 2-step improvement in the Diabetic Retinopathy Severity Scale at 40 we
MT NewswiresApr 18 15:17 ET
Ocular Therapeutix Highlights Early Data From Diabetes-Related Eye Disorder
On Thursday, Ocular Therapeutix Inc (NASDAQ:OCUL) announced topline results from the Phase 1 HELIOS study evaluating Axpaxli versus sham control in patients with moderately severe to severe non-prolif
BenzingaApr 18 13:37 ET
Ocular Therapeutix Shares Dive on Axpaxli Trial Results
By Dean Seal Shares of Ocular Therapeutix fell after the company reported topline data for a Phase 1 trial of its diabetic retinopathy drug candidate Axpaxli and said it would accelerate to Phase 3.
WSJApr 18 13:06 ET
Why Las Vegas Sands Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Las Vegas Sands Corp. (NYSE:LVS) fell sharply during Thursday's session despite better-than-expected first-quarter results.The company reported quarterly adjusted earnings of 75 cents per sh
BenzingaApr 18 11:32 ET
Express News | Ocular Therapeutix Shares Are Trading Lower. The Company Announced Topline Results From the Phase 1 HELIOS Study Evaluating AXPAXLI in Patients With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy
Moomoo 24/7Apr 18 11:31 ET
Ocular Marks Early-stage Trial Win for Diabetic Retinopathy Candidate
Seeking AlphaApr 18 07:30 ET
Express News | Ocular Therapeutix - 46.2% of Patients Showed a 1- or 2-Step Improvement in Diabetic Retinopathy Severity Scale (Drss) at 40 Weeks in Axpaxli Arm
Moomoo 24/7Apr 18 07:00 ET
Express News | Ocular Therapeutix Inc - Axpaxli Was Generally Well Tolerated With No Inflammation Observed
Moomoo 24/7Apr 18 07:00 ET
Express News | Ocular Therapeutix Inc - No Patients in Axpaxli Group Experienced Worsening in Drss Compared to 12.5% in Control Arm at 40 Weeks
Moomoo 24/7Apr 18 07:00 ET
Express News | Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for Axpaxli™ in Diabetic Retinopathy
Moomoo 24/7Apr 18 07:00 ET
Analysts Offer Insights on Healthcare Companies: Walgreens Boots Alliance (WBA), Ocular Therapeutix (OCUL) and Elevance Health (ELV)
TipRanksApr 17 05:10 ET
ENPH, OCUL and ITCI Are Among After Hour Movers
Seeking AlphaApr 16 17:02 ET
The Analyst Verdict: Ocular Therapeutix In The Eyes Of 8 Experts
Across the recent three months, 8 analysts have shared their insights on Ocular Therapeutix (NASDAQ:OCUL), expressing a variety of opinions spanning from bullish to bearish.The table below summarizes
BenzingaApr 16 13:01 ET
No Data
No Data